"sales have increased quarter on quarter ... " 4C statement should be due Monday I assume ? While MC remains the driver of upside, further revenues from nutraceuticals can only help.
The company has now made several mentions of MC and the US FDA's attention on Opioid crisis - It must be fair to say the FDA will not be able to dismiss hard fact based results from tests such as on starting at Royal North Shore
this has just not been the case in past because no data was available
because of the status of MC as a highly classified and regulated drug in both US (schedule 1 same as heroin etc) and Schedule 8 in Aus, that evidence or factual outcomes from research has just not been available -research was just too hard to do - while this always takes longer than you think, when it happens, it will change things very quickly.
market cap now circa 100 mill - if they were to achieve an FDA approved product for pain management on the back of the current RNS studies, the stock will have a market cap many 10's of multiples of current levels. This is really only 6-12months before we will have a good idea if this is a possible outcome
with the products and studies in place, the outlook here remains compelling
MDC Price at posting:
60.0¢ Sentiment: Hold Disclosure: Held
(20min delay)